medigraphic.com
ISSN 1729-519X (Print)

2012, Number 2

<< Back Next >>

Revista Habanera de Ciencias Médicas 2012; 11 (2)

Infection by helicobacter pylori associated with gastric malignant in Guerrero state, Mexico. 2001-2011

Escobar HED, Cantelar DFN, Capó DV, Martínez MI, Terán PMA, Cathcart RF

Language: Spanish
References: 28
Page:
PDF size: 71.56 Kb.


ABSTRACT

Introduction:The association between Helicobacter pylori and the gastric malignant has been extensively demonstrated, in relation to this, the WHO determined that the microorganism is a carcinogen agent proved from group I. In Mexico the prevalence of infection by this bacterium it is high.
Objective: Evaluation of the relationship between the socio-demographic, clinical-endoscopic and histopathological variables with the different kinds of gastric malignant in Helicobacter pylori positive and negative patients. Patients and methods: An investigation was carried out to determine the kind of association in a population of the south region of Mexico. The type of research is retrospective, descriptive and inferential, 214 cases with gastric adenocarcinoma and lymphoma associated to the mucosal (MALT) were studied, they were diagnosed from 2001 to 2011, of which 99 had Helicobacter pylori. Statistical techniques to evaluate the possible relationship between variables were used. Procedures: Arithmetic mean and standard deviation, percentages and its errors. Techniques: Chi square test for contingency tables, correlation of Spearman´s range, population parameter estimation, related percentage comparison.
Results: It was found meaningful associations between the histologic diagnostic and ages, blood serotype, antecedent of relatives with cancer and the symptomatology (dyspepsia and alarm signs), and very meaningful association between the presence of Helicobacter pylori with alive, deceased and the histologic diagnostic. It was determined that diffuse adenocarcinoma appears between a 48,8% and 62,4% with a probability of the 95% in the population with this characteristics, likewise, the percentage of neoplasm/toumor within endoscopic diagnosis ranges between 68,4% and 80,6% with a 95% probability. The interval of confidence with the 99% of certainty for the age in which these illnesses appear it moves between 56 and 62 years.
Conclusions: It has been proved that the socio-demographic, clinical-endoscopic and histologic characteristics of these patients with adenocarcinoma and lymphoma MALT have an influence in the final diagnostic, evolution and prognostic. The presence of Helicobacter pylori in these patients was determining for their survival.


REFERENCES

  1. Blaser M. Parasitism by the slow bacteria Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest. 1994;94:4-8.

  2. Blazer MJ. Campilobacter and related species Helicobacter pylori and related organism. En: Mandel GL, Bennett JE, Doping R, editores. Principles and practice of infectious disease. Nueva York: Churchill Livingstone; 1995: 1948-64.

  3. Gutiérrez B, Vidal T, Valmaña C, Camou C. Infección por Helicobacter pylori en Santo Domingo, República Dominicana. Rev Cubana Invest Biomed. 2006;25 (4):50-6.

  4. González-Carbajal Pascual M. Alteraciones del tracto digestivo superior e infección por Helicobacter pylori. Rev Cubana Med Gen Integr [Internet]. 2004 [citado el 9 de enero de 2010]. Disponible en: http://www.bvs.sld.cu/revistas/med/vol.43_5-6_04/med5-05.htm

  5. 5.Peek RM. Helicobacter pylori strain-specific modulation of gastric mucosal cellular turnover: implications for carcinogenesis. J Gastroenterol. 2002; 37(Suppl. 13):10-6.

  6. 6.Thomas JE, Gibson GR, Darboe MK, Dale A, Weaver LT. Isolation of Helicobacter pylori from human heces. Lancet. 1992;340:1194-5.

  7. 7.Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):33-43.

  8. González M, Carbajal P. Aspectos epidemiológicos de mayor relieve de la infección por Helicobacter pylori. En: Helicobacter pylori ¿el tercer dogma? Madrid: Editorial Valle del Ebro; 2003: 83-112.

  9. 9.Rollán A. Erradicación de Helicobacter pylori en países en desarrollo. Rev. Med. Chile. 1997; 125:939-949.

  10. Hansen P, Go M, Varming K, Andersen L, Genta R, Graham D. Proinfammatory activation of neutrophils and monocytes by Helicobacter pylori in patients with different clinical presentations. InfectImmun. 1999;67:3171-4.

  11. Jofré M, Cornejo N, Cortés M, Muñoz I, Pérez E, Rodríguez J, et al. Frecuencia de Helicobacter pylori en muestras de biopsias gástricas obtenidas del Hospital Regional de Antofagasta. Anal Microbiol. 1994;2:1-3.

  12. Malfertheiner P, Megraud F, O´ Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection; the Maastricht III Consensus Report. Gut. 2007; 56(56):782-81.

  13. Klein P, Gilman R, Barau R, Díaz F, Smith E, Graham D. The epidemiology of Helicobacter pylori in Peruvian children between 6 and 30 months of age.Am JGastroenterol. 1994;89:2196-9.

  14. Crawford JM. Aparato gastrointestinal. En: Cotran RS, Kumar V, Collins T, editores. Patología estructural y funcional. Madrid: Mc-Graw-Hill-Interamericana; 2000;(I):821-36.

  15. 15.Torres J, Leal Herrera Y, Pérez Pérez G, Gómez A, Carmolinga Ponce M, Cedillo Rivera R, et al. A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis. 1998;178:1089-94.

  16. Shimizu S, Uchiyama A, Mizumoto K. Laparoscopically assisted distal gastrectomy for early gastric cancer is superior to open surgery? Surg Endoscopy. 2000;14(1):27-31.

  17. Soto AV, Cruz OH, Salas GJ, Murgía D. Cáncer gástrico: caso clínico- patológico. Rev Fac Med UNAM. 2001;44(3):133-6.

  18. Hahm K, Lee J. Possibility of chemoprevention by the eradication of Helicobacter pylori: Oxidative DNA damage and apoptosis in infection. Am J Gastroenterol.1997;92:1853-7.

  19. Delgado O, Sobrino Cossío S, García García L, Marroquín Chavira A, Hernández Mote R, Gariglio P. Microbiología: relación entre la infección por Helicobacter pylori y el desarrollo de metaplasia en pacientes con gastritis crónica. RevAsocMexBioqClín. 2006;30(1):1-2.

  20. Valdés-Dapena Vivanco MM. Campylobacter, Helicobacter y microorganismos afines. En: Llop Hernández A, Valdés-Dapena Vivanco MM, Zuazo Silva JL, editores. Microbiología y parasitología médicas. La Habana: Ciencias Médicas; 2009: 347-54.

  21. Allexander GA. Association of Helicobacter pylori infection with gastric cancer. Military Medicine. 2000;165(1):21-7.

  22. 22.Tejer CP, Ziogas A, Kurosaki T, Butler J, Antón-Culver H. Asian patients with gastric carcinoma in the United States exhibit unique clinical features and superior overall cancer specific survival rates. Cancer. 2000;89(9):1883-92.

  23. Registro histopatológico de neoplasias malignas en México. México: RHNM; 2000.

  24. Marshall B. Helicobacter pylori. Am J Gastroenterol. 1994;89:116-27.

  25. Roggero E, De Boni M, Barbazza R. Regression of high grade B-cell gastric lymphoma after eradication of Helicobacter pylori infection. Gut. 1999;45:(suppl. V).

  26. Sharara AI, Chaar HF, Aoun E, Abdul-Baki H, Araj GF, Kanj SS. Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter. 2006;11(4):231-6.

  27. Pisters PW, Kelsen DP, Powell SM, Tepper JE. Cancer of stomach. En: DeVita VT, Hellman S, Rosenberg SA, editores. Principles and practice of oncology. 7ma ed. Philadelphia: Lippincot, William and Wilkins; 2005: 909-44.

  28. Ramírez Ramos A, LeeyCasella J, Mendoza Requena D, Guerra Valencia J. Temas de revisión: Helicobacter pylori, epidemiología, diagnóstico, tratamiento, consensos mundiales: experiencia en el Perú. Diagnóstico. 2003;19(1):143-9.




2020     |     www.medigraphic.com